A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment

References

• Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990–2010. Blood. 2014;123:615–624.
   PubMed Web of Science ®Google Scholar
• Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822.
   PubMed Web of Science ®Google Scholar
• Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoeisis. Transfusion. 2012;52:1584–1592.
   PubMed Web of Science ®Google Scholar
• Gereklioglu C, Asma S, Korur A, et al. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32(3):604–607.
   PubMed Web of Science ®Google Scholar
• Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol. 2009;44(7):838–845.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Gasche C, Bettenworth D, et al. European Crohn’s and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211–222.
   PubMed Web of Science ®Google Scholar
• Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood products: an Australian perspective. Curr Opin Anaesthesiol. 2012;25:66–73.
   PubMed Web of Science ®Google Scholar
• Shander A, Spence RK, Auerbach M. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents? Transfusion. 2010;50:719–732.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739–756.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Ainsworth M, Coskun M, et al. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine (Baltimore). 2015;94(23):e963.
   PubMed Web of Science ®Google Scholar
• Medicines.org.uk. Monofer 100mg/ml solution for injection/infusion. Summary of Product Characteristics. [Last accessed 2018 Oct 3]. Available from: https://www.medicines.org.uk/emc/product/5676/smpc
   Google Scholar
• Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53–64.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011 [cited 2018 Sep 5]. Available from: http://handbook.cochrane.org
   Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–748.
   PubMed Web of Science ®Google Scholar
• Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182–1192.
   PubMed Web of Science ®Google Scholar
• Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101(1):67–73.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108(12):1877–1888.
   PubMed Web of Science ®Google Scholar
• Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anaemia. Am J Hematol. 2017;92(3):286–291.
   PubMed Web of Science ®Google Scholar
• Evstatiev R, Marteau P, Iqbal T, et al. FERGI study group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846–53.e1–2.
   PubMed Web of Science ®Google Scholar
• Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anaemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833–842.
   PubMed Web of Science ®Google Scholar
• Mahey R, Kriplani A, Mogili KD, et al. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. Int J Gynaecol Obstetrics. 2016;133(1):43–48.
   PubMed Web of Science ®Google Scholar
• Aksan A, Işık H, Radeke HH, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1303–1318.
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68(5):677–690.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Venturini S, Meregaglia M, et al. Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials. Clin Drug Investig. 2016;36(3):177–194.
   PubMed Web of Science ®Google Scholar
• Szucs TD, Blank PR, Schwenkglenks M, et al. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia. Oncology. 2011;81(1):45–49.
   PubMed Web of Science ®Google Scholar
• Moore RA, Gaskell H, Rose P, et al. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4.
   PubMedGoogle Scholar
• Reinisch W, Lindgren S. Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapies. Aliment Pharmacol Ther. 2017;46(7):704–705.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25(6):529–535.
   PubMed Web of Science ®Google Scholar
• Emrich IE, Lizzi F, Seiler-Mußler S, et al. Hypophosphatemia after high dosage iron substitution with ferric carboxymaltose (FCM) and iron isomaltoside (IM) – the randomised controlled HOMe AFers 1 Trial. Abstract 3627. American Society of Hematology 2018 Annual Meeting, San Diego, CA, USA.
   Google Scholar
• Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. Clinicoecon Outcomes Res. 2017;9:475–483.
   PubMed Web of Science ®Google Scholar
• Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv. 2017;14(12):1439–1446.
   PubMed Web of Science ®Google Scholar